The Global Immune–Nutrition–Inflammation Index (GINI) as a Candidate Prognostic Marker in Patients with Cutaneous Squamous Cell Carcinoma Treated with Cemiplimab
Simple Summary Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Although anti-PD-1 immunotherapy has significantly improved treatment outcomes for patients with advanced disease, a substantial portion of individuals do not respond, and reliable pretreatment tools to predict succes...